PARP1 and neoplasm: In this study, we developed a new compound ZC-22, which can effectively inhibit the activity of both PARP and CDK4/6 and displayed better anti-tumor efficacy than PARPi Olaparib and CDK4/6i Abemaciclib monotherapy, or even combination therapy in both cell and mouse models.